Maren Darsow

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Long-Term Morbidity Following Axillary Dissection in Breast Cancer Patients – Clinical Assessment, Significance for Life Quality and the Impact of Demographic, Oncologic and Therapeutic Factors

Thorsten Kuehn, Wolfgang Klauss, Maren Darsow et al. · Breast Cancer Research and Treatment · 2000 · 234 citations

Medicine, Oncology, Surgery +16

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Ulrike Nitz, Oleg Gluz, Hans Kreipe et al. · Therapeutic Advances in Medical Oncology · 2020 · 46 citations · Full text

Medicine, Endocrinology, Oncology +17

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Oleg Gluz, Sherko Küemmel, Ulrike Nitz et al. · Annals of Oncology · 2023 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial

Nadia Harbeck, Oleg Gluz, Sherko Küemmel et al. · Cancer Research · 2021 · 12 citations

Medicine, Endocrinology, Oncology +17